Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780439 | 0.83 | CYP1A2 (0.42) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL779717 | 0.82 | CFTR (0.41) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL777238 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL2700240 | 0.78 | CFTR (0.59) | ALDH1A1GAAUSP2MEN1KMT2A | |
| SCHEMBL4319820 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL1800378 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL779809 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL5570426 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MAPTSMN1; SMN2GAAALPG | |
| SCHEMBL9949805 | 0.74 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL11704934 | 0.74 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421217-B2 | Pyrazine derivative or salt thereof, and use of same | FUJIFILM CORPORATION (JP) | 2025-09-23 | — | — | US | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| EP-4052760-B1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | FUJIFILM CORP (JP) | 2024-03-13 | — | — | EP | disclosed |
| EP-4052760-A1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | FUJIFILM Corporation (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220259185-A1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | FUJIFILM CORPORATION (JP) | 2022-08-18 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005046683-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| JP-2002193846-A | METHOD FOR PRODUCING TRIFLUOROPROPENYL COMPOUND | SUMITOMO CHEM CO LTD | 2002-07-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | ALDH1A1 2876/4885MAPT 3247/4885SMN1; SMN2 2756/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | ALDH1A1 4150/4885MAPT 4688/4885SMN1; SMN2 1852/4885 |
| US-12421217-B2 | Pyrazine derivative or salt thereof, and use of same | DHODH, IDH1, IDH2 | ALDH1A1 117/4885MAPT 4437/4885SMN1; SMN2 4686/4885 |
| US-20220259185-A1 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | DHODH, IDH1, IDH2 | ALDH1A1 117/4885MAPT 4437/4885SMN1; SMN2 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.